Episodic eosinophilia-myalgia-like syndrome in a patient without l-tryptophan use: Association with eosinophil activation and increased serum levels of granulocyte-macrophage colony-stimulating factor

Bruce S. Bochner, Baruch Friedman, Guha Krishnaswami, Robert P. Schleimer, Lawrence M. Lichtenstein, Claus Kroegel

Research output: Contribution to journalArticle

Abstract

We have studied a patient with recurrent bouts of angioedema, myalgia, and eosinophilia that was not due to L-tryptophan ingestion. Peripheral blood eosinophils (EOSs) during exacerbations of his illness displayed characteristics of "activation," including hypodense phenotype and increased responsiveness to platelet-activating factor (PAF) in vitro with respect to expression of CD11b surface adhesion proteins. Elevated serum levels of granulocyte-macrophage colony-stimulating factor (GM-CSF) bioactivity were also detected, whereas interleukin-3 and interleukin-5 levels were not increased. During treatment with glucocorticoids, all clinical symptoms resolved, EOSs decreased in number and became normodense, PAF responsiveness diminished, and GM-CSF levels returned to normal. During glucocorticoid tapering, a subsequent clinical relapse was again associated with EOS hypodensity, increased PAF responsiveness, and increased serum GM-CSF levels. Although this patient satisfies the diagnostic criteria for eosinophilia-myalgia syndrome, the episodic and profound nature of exacerbations and response to therapy in the absence of L-tryptophan usage suggests a possible overlap with the syndrome of episodic angioedema and eosinophilia. In vitro studies suggest that GM-CSF may play a role in the eosinophilia, EOS activation, and pathophysiology of disease in this patient and demonstrate resolution of these abnormalities during glucocorticoid therapy. The efficacy of glucocorticoid therapy in some hypereosinophilic states may therefore be mediated, at least in part, via reduction of GM-CSF production and / or EOS activation.

Original languageEnglish (US)
Pages (from-to)629-636
Number of pages8
JournalThe Journal of Allergy and Clinical Immunology
Volume88
Issue number4
DOIs
StatePublished - 1991

Fingerprint

Eosinophilia-Myalgia Syndrome
Granulocyte-Macrophage Colony-Stimulating Factor
Eosinophils
Tryptophan
Glucocorticoids
Platelet Activating Factor
Eosinophilia
Angioedema
Serum
Interleukin-3
Myalgia
Interleukin-5
Therapeutics
Membrane Proteins
Eating
Phenotype
Recurrence

Keywords

  • Eosinophil activation
  • GM-CSF
  • myalgia

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Episodic eosinophilia-myalgia-like syndrome in a patient without l-tryptophan use : Association with eosinophil activation and increased serum levels of granulocyte-macrophage colony-stimulating factor. / Bochner, Bruce S.; Friedman, Baruch; Krishnaswami, Guha; Schleimer, Robert P.; Lichtenstein, Lawrence M.; Kroegel, Claus.

In: The Journal of Allergy and Clinical Immunology, Vol. 88, No. 4, 1991, p. 629-636.

Research output: Contribution to journalArticle

Bochner, Bruce S. ; Friedman, Baruch ; Krishnaswami, Guha ; Schleimer, Robert P. ; Lichtenstein, Lawrence M. ; Kroegel, Claus. / Episodic eosinophilia-myalgia-like syndrome in a patient without l-tryptophan use : Association with eosinophil activation and increased serum levels of granulocyte-macrophage colony-stimulating factor. In: The Journal of Allergy and Clinical Immunology. 1991 ; Vol. 88, No. 4. pp. 629-636.
@article{03bdad229fa44d22b5bac40e00af5fc6,
title = "Episodic eosinophilia-myalgia-like syndrome in a patient without l-tryptophan use: Association with eosinophil activation and increased serum levels of granulocyte-macrophage colony-stimulating factor",
abstract = "We have studied a patient with recurrent bouts of angioedema, myalgia, and eosinophilia that was not due to L-tryptophan ingestion. Peripheral blood eosinophils (EOSs) during exacerbations of his illness displayed characteristics of {"}activation,{"} including hypodense phenotype and increased responsiveness to platelet-activating factor (PAF) in vitro with respect to expression of CD11b surface adhesion proteins. Elevated serum levels of granulocyte-macrophage colony-stimulating factor (GM-CSF) bioactivity were also detected, whereas interleukin-3 and interleukin-5 levels were not increased. During treatment with glucocorticoids, all clinical symptoms resolved, EOSs decreased in number and became normodense, PAF responsiveness diminished, and GM-CSF levels returned to normal. During glucocorticoid tapering, a subsequent clinical relapse was again associated with EOS hypodensity, increased PAF responsiveness, and increased serum GM-CSF levels. Although this patient satisfies the diagnostic criteria for eosinophilia-myalgia syndrome, the episodic and profound nature of exacerbations and response to therapy in the absence of L-tryptophan usage suggests a possible overlap with the syndrome of episodic angioedema and eosinophilia. In vitro studies suggest that GM-CSF may play a role in the eosinophilia, EOS activation, and pathophysiology of disease in this patient and demonstrate resolution of these abnormalities during glucocorticoid therapy. The efficacy of glucocorticoid therapy in some hypereosinophilic states may therefore be mediated, at least in part, via reduction of GM-CSF production and / or EOS activation.",
keywords = "Eosinophil activation, GM-CSF, myalgia",
author = "Bochner, {Bruce S.} and Baruch Friedman and Guha Krishnaswami and Schleimer, {Robert P.} and Lichtenstein, {Lawrence M.} and Claus Kroegel",
year = "1991",
doi = "10.1016/0091-6749(91)90157-J",
language = "English (US)",
volume = "88",
pages = "629--636",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Episodic eosinophilia-myalgia-like syndrome in a patient without l-tryptophan use

T2 - Association with eosinophil activation and increased serum levels of granulocyte-macrophage colony-stimulating factor

AU - Bochner, Bruce S.

AU - Friedman, Baruch

AU - Krishnaswami, Guha

AU - Schleimer, Robert P.

AU - Lichtenstein, Lawrence M.

AU - Kroegel, Claus

PY - 1991

Y1 - 1991

N2 - We have studied a patient with recurrent bouts of angioedema, myalgia, and eosinophilia that was not due to L-tryptophan ingestion. Peripheral blood eosinophils (EOSs) during exacerbations of his illness displayed characteristics of "activation," including hypodense phenotype and increased responsiveness to platelet-activating factor (PAF) in vitro with respect to expression of CD11b surface adhesion proteins. Elevated serum levels of granulocyte-macrophage colony-stimulating factor (GM-CSF) bioactivity were also detected, whereas interleukin-3 and interleukin-5 levels were not increased. During treatment with glucocorticoids, all clinical symptoms resolved, EOSs decreased in number and became normodense, PAF responsiveness diminished, and GM-CSF levels returned to normal. During glucocorticoid tapering, a subsequent clinical relapse was again associated with EOS hypodensity, increased PAF responsiveness, and increased serum GM-CSF levels. Although this patient satisfies the diagnostic criteria for eosinophilia-myalgia syndrome, the episodic and profound nature of exacerbations and response to therapy in the absence of L-tryptophan usage suggests a possible overlap with the syndrome of episodic angioedema and eosinophilia. In vitro studies suggest that GM-CSF may play a role in the eosinophilia, EOS activation, and pathophysiology of disease in this patient and demonstrate resolution of these abnormalities during glucocorticoid therapy. The efficacy of glucocorticoid therapy in some hypereosinophilic states may therefore be mediated, at least in part, via reduction of GM-CSF production and / or EOS activation.

AB - We have studied a patient with recurrent bouts of angioedema, myalgia, and eosinophilia that was not due to L-tryptophan ingestion. Peripheral blood eosinophils (EOSs) during exacerbations of his illness displayed characteristics of "activation," including hypodense phenotype and increased responsiveness to platelet-activating factor (PAF) in vitro with respect to expression of CD11b surface adhesion proteins. Elevated serum levels of granulocyte-macrophage colony-stimulating factor (GM-CSF) bioactivity were also detected, whereas interleukin-3 and interleukin-5 levels were not increased. During treatment with glucocorticoids, all clinical symptoms resolved, EOSs decreased in number and became normodense, PAF responsiveness diminished, and GM-CSF levels returned to normal. During glucocorticoid tapering, a subsequent clinical relapse was again associated with EOS hypodensity, increased PAF responsiveness, and increased serum GM-CSF levels. Although this patient satisfies the diagnostic criteria for eosinophilia-myalgia syndrome, the episodic and profound nature of exacerbations and response to therapy in the absence of L-tryptophan usage suggests a possible overlap with the syndrome of episodic angioedema and eosinophilia. In vitro studies suggest that GM-CSF may play a role in the eosinophilia, EOS activation, and pathophysiology of disease in this patient and demonstrate resolution of these abnormalities during glucocorticoid therapy. The efficacy of glucocorticoid therapy in some hypereosinophilic states may therefore be mediated, at least in part, via reduction of GM-CSF production and / or EOS activation.

KW - Eosinophil activation

KW - GM-CSF

KW - myalgia

UR - http://www.scopus.com/inward/record.url?scp=0025748785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025748785&partnerID=8YFLogxK

U2 - 10.1016/0091-6749(91)90157-J

DO - 10.1016/0091-6749(91)90157-J

M3 - Article

C2 - 1918729

AN - SCOPUS:0025748785

VL - 88

SP - 629

EP - 636

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 4

ER -